Skip to main content
main-content

Sodium-glucose co-transporter-2 inhibitors

News

11-14-2017 | Canagliflozin | News

Canagliflozin benefits may extend to primary prevention

Further analysis of the CANVAS trial suggests that the benefits of canagliflozin treatment are broadly consistent in type 2 diabetes patients with and without pre-existing cardiovascular disease,

09-20-2017 | Non-alcoholic fatty liver disease | EASD 2017 | News

NAFLD: The associated risks and potential treatments

Researchers presented the results of several studies investigating the risks associated with nonalcoholic fatty liver disease and potential treatment strategies at the EASD annual meeting in Lisbon, Portugal.

09-19-2017 | Sotagliflozin | EASD 2017 | News

Sotagliflozin as adjunct therapy to insulin ‘might be a treatment option’ for type 1 diabetes

Sotagliflozin may be an effective add-on therapy to insulin for patients with type 1 diabetes, but the benefits are less clear in a young adult population, suggest the results of two studies presented at the EASD annual meeting in Lisbon, Portugal.

Read more

Related topics

Superior

Related

Specific

Opinion

11-22-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Sodium-glucose co-transporter-2 inhibitors in acute coronary syndrome

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of sodium-glucose co-transporter-2 inhibitors in patients affected by acute coronary syndromes.

01-13-2017 | Cardiovascular outcomes | Editorial | Article

Clinical implications of cardiovascular outcomes trials in type 2 diabetes

What do the results of CVOTs mean for practicing clinicians? Editorial board member Carol Wysham reviews the latest evidence and guidelines for reducing CV risk in patients with type 2 diabetes.

In depth

08-22-2017 | Canagliflozin | Podcast | Audio

Dissecting the CANVAS trial

Listen to editorial board members and CANVAS investigators Carol Wysham and Lori Berard discussing the efficacy and safety findings of the trials.

Original research

11-01-2016 | Type 2 diabetes | OriginalPaper | Article

Implications of the EMPA-REG Trial for Clinical Care and Research

An expert review of the EMPA-REG trial’s main findings, mechanisms that could explain its results, suggestions for ways in which clinical care may be influenced, and directions for future research.

Stamatouli AM & Inzucchi SE. Curr Diab Rep 2016;16:131. doi:10.1007/s11892-016-0822-7

09-30-2016 | Type 2 diabetes | Article

Combination therapy with glucagon-like peptide-1 analogues and sodium-glucose cotransporter-2 inhibitors in the management of diabesity: the real world experience

Results from this retrospective cohort study show that combination therapy of glucagon-like peptide-1 (GLP-1) agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors is a promising option for patients with diabesity.

Deol H et al. Endocrine 2017;55:173–178. doi:10.1007/s12020-016-1125-0

Journal articles and book chapters

10-11-2017 | Cardiovascular disorders | Review | Article

Updates on cardiovascular outcome trials in diabetes

This review summarizes the results of the DEVOTE, CANVAS, EXSCEL, and ACE trials that tested the cardiovascular safety of insulin degludec, canagliflozin, once-weekly exenatide, and acarbose, respectively.

Schnell O et al. Cardiovasc Diabetol 2017;16:128. doi:10.1186/s12933-017-0610-y

09-27-2017 | Dyslipidemia | Review | Article

Treatment of dyslipidemia in diabetes: Recent advances and remaining questions

This review summarizes the current knowledge concerning diabetic dyslipidemia and cardiovascular disease (CVD), including specific strategies to reduce diabetes-associated CVD.

Chait A, Goldberg I. Curr Diab Rep 2017;17:112. doi:10.1007/s11892-017-0942-8

09-19-2017 | Hypertension | Practical approach | Article

A practical approach to hypertension management in diabetes

Hypertension is an important comorbidity of diabetes, contributing significantly to death and disability. This article provides a practical approach to managing hypertension in patients with diabetes.

Shaikh A. Diabetes Ther 2017;8:981–989. doi:10.1007/s13300-017-0310-3

Case reports

04-26-2016 | Neonatal diabetes | Case report | Article

Not all diabetes in infants is type 1: A case report

The authors present their experience with a patient with permanent neonatal diabetes, initially misdiagnosed as type 1 diabetes, who was successfully transitioned to oral sulfonylurea therapy after 37 years of insulin dependence.

Arce KM & Pantalone KM. Diabetes Ther 2016; 7: 369–375. doi:10.1007/s13300-016-0171-1

image credits